Literature DB >> 15004130

Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide.

Tamara R Anderegg, Thomas R Fritsche, Ronald N Jones.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 15004130      PMCID: PMC356839          DOI: 10.1128/JCM.42.3.1386-1387.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  2 in total

1.  Interpretive criteria for testing susceptibility of staphylococci to mupirocin.

Authors:  J E Finlay; L A Miller; J A Poupard
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria.

Authors:  C L Friedrich; D Moyles; T J Beveridge; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

  2 in total
  4 in total

1.  Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.

Authors:  Thomas R Fritsche; Paul R Rhomberg; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

Review 2.  Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections.

Authors:  Haroon Mohammad; Shankar Thangamani; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  Protocol for human placental mesenchymal stem cell therapy in a murine model of intra-abdominal infection of hypervirulent Klebsiella.

Authors:  Li-Tzu Wang; Sheng-Kang Chiu; Wei Lee; L Kristopher Siu; Ko-Jiunn Liu; Men-Luh Yen; B Linju Yen
Journal:  STAR Protoc       Date:  2021-02-05

4.  Evaluation of cinnamon extract effects on clbB gene expression and biofilm formation in Escherichia coli strains isolated from colon cancer patients.

Authors:  Faezah Kosari; Mohammad Taheri; Abbas Moradi; Reza Hakimi Alni; Mohammad Yousef Alikhani
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.